BioCentury | Oct 26, 2015
Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...
BC Week In Review | Apr 27, 2015
Company News

Curadev, Roche deal

Curadev and Roche partnered to develop inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase ( TDO2 ; TDO ) to treat cancer. The deal gives Roche exclusive, worldwide rights to develop and commercialize Curadev’s lead compound,...
BC Extra | Apr 21, 2015
Company News

Curadev, Roche partner to develop IDO1/TDO inhibitors for cancer

Curadev Pharma Pvt. Ltd. (New Delhi, India) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to develop inhibitors of indoleamine 2,3-dioxygenase 1 ( IDO1 ) and tryptophan 2,3-dioxygenase ( TDO2 ; TDO ) to treat cancer. The deal gives Roche exclusive, worldwide...
Items per page:
1 - 3 of 3